Table 7.
Cardiovascular risk factors and current leflunomide use
| Risk factor | No leflunomide (N = 138) | Current leflunomide use (N = 31) | P value | Beta* (95%CI) | P value* |
|---|---|---|---|---|---|
| Systolic BP (mm Hg) | 132.6 ± 20.3 | 136.6 ± 20.2 | 0.28 | 5.7 (−0.32–11.73) | 0.07 |
| Diastolic BP (mm Hg) | 74.6 ± 10.6 | 76.5 ± 11.6 | 0.33 | 1.41 (−2.54–5.35) | 0.49 |
| HDL (mg/dL) | 46.4 ± 14.1 | 47.1 ± 13.4 | 0.69 | 0.74 (−4.39–5.88) | 0.78 |
| LDL (mg/dL) | 111.5 ± 33.3 | 117.9 ± 34.2 | 0.28 | 8.40 (−5.06–21.86) | 0.22 |
| Triglycerides (mg/dL) | 145.0 ± 187.8 | 143.0 ± 132.2 | 0.59 | 0.02 (−0.19–0.23) | 0.86 |
| Glucose (mg/dL) | 93.0 ± 19.2 | 83.6 ± 13.4 | 0.01 | −8.12 (−13.84–−2.41) | 0.006 |
| Homocysteine (µmol/L) | 10.37 ± 3.20 | 11.09 ± 3.97 | 0.68 | 0.50 (−0.69–1.68) | 0.41 |
| F2-Isoprostanes (ng/mg Cr) | 3.36 ± 4.02 | 4.07 ± 2.59 | 0.03 | 0.19 (−0.06–0.44) | 0.15 |
*
Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reflect mean differences in log-units than raw units.